How GLP-1s Are Rewiring the Treatment of Heart, Kidney, and Liver Disease 

Introduction to the New Health Journey

Wegovy, Zepbound, Ozempic, and other GLP-1 meds are famous for being effective weight loss injections. But did you know they’re used for heart, kidney, and liver disease treatment? Forget about what Hollywood says about Ozempic for a second. GLP-1s are actually multi-organ protective agents that can treat diabetes, inflammation, and a ton of other medical conditions. 

In this guide, we will go over how GLP-1 works, how it can protect the heart, kidney, and liver, and side effects to know about.

What Is GLP-1?

GLP-1 meds include the prescription drugs of Ozempic and Wegovy (semaglutide), as well as Mounjaro and Zepbound (tirzepatides). These injections mimic the natural gut hormone of GLP-1 to treat diabetes symptoms and reduce obesity. Pop culture has made GLP-1 meds famous for weight loss, but it doesn’t only eliminate food noise to cause weight loss: it can greatly improve diabetes Type 2 patients’ health. 

Semaglutides are single glucagon-like peptide-1 (GLP-1) receptor agonists, whereas tirzepatides work on both dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1. Different medications can have different approval details. For example, tirzepatide is approved for 10-year-olds and above for T2DM, while semaglutide is approved for 12 years and older.  

The Heart: Reducing Cardiovascular Risk and Heart Failure

The heart pumps blood throughout the body. GLP-1 meds can impact heart health in a positive way by: 

* Reducing systemic inflammation 

* Lowering blood pressure 

* Improving blood vessel elasticity

There was a SELECT study on semaglutide effects on cardiovascular outcomes in people with overweight or obesity. It showed a 20% reduction in major adverse cardiovascular events like stroke and heart attacks. It reduced heart failure-related hospitalization numbers, and decreased cardiovascular death numbers. This has been a huge breakthrough since studies show other medications and lifestyle changes did not seem to make as much of a difference as semaglutide. 

The cardioprotective effects of GLP-1 meds are not completely understood yet and still need to be studied more, but studies clearly show that these cardioprotective effects exist and are notable. A 20% reduction in major negative events is very promising for those with heart concerns, especially those who are overweight or obese. 

There is also a clinical focus on treating HFpEF (heart failure with preserved ejection fraction) in patients with obesity. It is a complex syndrome that affects around half of the American heart failure cases, leading to reduced quality of life and mortality. A study of semaglutide in HFpEF patients showed that symptoms and physical limitations (e.g. exercise function) were notably reduced after taking semaglutide. 

GLP-1 for cardiac health 

We’re currently seeing a shift in cardiologists as they go from recommending heart-health high-risk patients to manage cholesterol and blood pressure to actively prescribing GLP-1s as a meaningful preventative shield. Lifestyle changes of course may still be advised, and it is important to listen to your physician’s instructions, but it appears that GLP-1s can seriously help with heart health. 

If you have cardiac concerns, it is a good idea to speak with your physician about whether semaglutide may be able to help you with your symptoms (or otherwise).  

The Kidneys: Halting Chronic Kidney Disease (CKD)

Chronic Kidney Disease (CKD) is a serious condition where the kidneys are damaged and cannot filter blood properly. Waste can build up to dangerous amounts in the body, and millions are constantly on the brink of kidney dialysis. 

GLP-1 can have a protective effect on the kidneys and potentially stall end-stage renal disease. The meds have shown to be able to reduce the oxidative stress experienced by the kidneys, decrease harmful protein filtration (albuminuria), and improve the kidney’s filtering lifespan. 

Let’s take a look at the FLOW trial of semaglutide on CKD patients. 3533 patients participated in the study, with patients having diabetes type 2 and CKD. Half of the patients took semaglutide, and a follow-up was done in the years following to obtain results. 

The research results provide positive results for semaglutide use in those with type 2 diabetes/CKD. They suggest that semaglutide notably can:

* Reduce the risk of kidney problems 

* Reduce the risk of death from kidney and cardiovascular causes 

A trial shows that tirzepatide can also be used to protect the kidneys. It may be done by reducing the urine protein (albuminuria, a major marker of kidney damage) and slowing down the decline in estimated glomerular filtration rate (eGFR). Patients with type 2 diabetes, obesity, and CKD may benefit from the cardiorenal protective qualities of the recently approved tirzepatide. 

The Liver: Dealing with MASH 

What is MASH? 

MASH stands for Metabolic Dysfunction-Associated Steatohepatitis (formerly known as NASH for nonalcoholic). It refers to the fibrosis (scarring) and inflammation of the liver caused by fat accumulation, and unfortunately is currently the leading driver of liver transplants.

MASH can reduce a person’s life expectancy by 2 to 4 years. An early diagnosis paired with lifestyle changes can help. But can GLP-1 help with MASH? 

GLP-1 effects on MASH and FDA approval  

Without FDA approval, a medication will carry unknown safety risks, manufacturing concerns, no proof of effectiveness, and other problems. If you want a medication to succeed, it likely needs FDA approval. 

Semaglutide was approved to treat moderate to severe MASH with liver fibrosis. Let’s take a look at the pivotal ESSENCE trial of semaglutide in MASH. In this trial, semaglutide was found to be *significantly associated* with improvements in MASH resolution and fibrosis (scarring) regression. Medical communities have become enthusiastic about using semaglutide to treat MASH, which has previously been harder to handle. 

Does GLP-1 Work Forever? 

Now, GLP-1s have been studied extensively, but our understanding of them is not complete. They can clearly reduce symptoms and bring about heart, kidney, and liver protecting abilities, but do these beneficial effects last forever? There have been scientific studies that raise the need for *more* studies before we can say just how good a GLP-1 or GIP medication can be over decades of usage. 

In 2025, a case study of a 46 year old woman with cirrhosis and obesity was published to challenge the Reversal of End-Stage Liver Fibrosis with Tirzepatide in MASH Cirrhosis. It asked whether tirzepatide can actually *reverse* MASH cirrhosis, or if it simply stalls it. 

Medical studies tend to require longitudinal studies over years, even decades, before fuller understanding is reached. As of now, studies have shown very promising and reliable treatment of various health concerns, primarily focusing on diabetes Type 2, as well as cardiovascular, kidney, and liver diseases. Obesity can clearly be treated by GLP-1s, as it is a very noticeable change amongst those who take GLP-1s. 

Economic and Insurance Challenges

One major issue that has been consistently associated with GLP-1 meds is that they can be quite inaccessible. Either people can’t get a prescription, or it is out of stock, or it is too expensive. 

GLP-1s have historically been categorized by health insurance companies as a lifestyle or vanity drug, instead of a lifesaving or necessary medication. This makes it much harder to get your insurance company to cover your GLP-1 costs. As a result, you may need to pay over $1,000 a month for GLP-1 medication out-of-pocket. 

Fortunately, the FDA has expanded GLP-1 approvals into heart, kidney, and liver treatment. This means insurance companies are starting to cover Ozempic, Wegovy, and other GLP-1 meds under the standard medical necessity criteria. 

If you have insurance, GLP-1 or GIP meds can potentially cost only $25 or so per month. Compared to treatment costs of serious heart, kidney, and liver diseases, this GLP-1 medication cost suddenly seems very cheap. Plus, medications like GLP-1 can essentially be like a long-term subscription that could save your life or greatly improve your quality of life in the long term. 

Future expectations and challenges of GLP-1 

GLP-1 needs to be consistently taken to maintain results. It may not be an effective cure for heart, kidney, or liver disease, but rather a long-term treatment that brings about protective qualities and weight loss effects. Many patients do see that if they stop taking GLP-1, they end up gaining all the weight they had lost back. Around two-thirds of people who stop injections will regain their weight within a year of stopping. 

It is possible to think about it like this: paying for a GLP-1 medication now could prevent or delay the astronomical costs of future heart attacks, dialysis, and liver transplants. Not to mention, of course, the medical necessity and stress of these events.

GLP-1 Side Effects

Medications always have side effects and it is important to know the potential risks associated with taking various types of GLP-1 meds. Make sure you read your prescription details and speak with your physician about your personal risks, since individual differences can result in different GLP-1 medication results. 

In general, GLP-1 meds can cause immediate side effects of:

* Nausea

* Stomach discomfort

* Diarrhea 

* Vomiting 

These short-term side effects can appear immediately after starting GLP-1 injections. Not everyone will get all of the symptoms, but a majority of people who go on GLP-1 will experience some sort of nausea or stomach symptom. There are also long-term side effects that may impact you if you take GLP-1 injections for a long time.

* Lean muscle mass loss (causing sunken cheeks)

* Gallbladder issues

* Thyroid tumors and/or cancer

* Pancreatitis 

In addition, there are some potential non-physical side effects to beware. Anhedonia is the inability to feel joy from something you know you once liked. GLP-1s can lower the volume on food noise (intrusive thoughts about food) and greatly reduce food cravings. This may make it less pleasurable to eat, which could have an adverse mental effect on those who struggle with the change. 

Those who take other medications may also risk interactions between the different drugs. Be sure to get individualized health advice from your licensed physician before starting GLP-1 injections since there can be rare but serious health effects. 

Conclusion: The New GLP-1 Wave of Treatments

GLP-1 or GIP meds like Ozempic or Zepbound have brought new hope to kidney, heart, and liver disease patients. Chronic diseases can truly be treated and managed through GLP-1 meds, ensuring better quality of life or reduced symptoms for patients. GLP-1 meds might not cure someone with diabetes or MASH or CKD, but these meds have positive effects on stalling diseases and making patients feel better. 

In the future, we can look forward to more FDA approved meds and GLP-1 formulations that promise even more protective qualities. Now, it’s a good time to speak with your physician to ask about how GLP-1 meds could help you.